Novel pulse device for diagnosis of peripheral arterial disease (NOTEPAD): ISRCTN13301188

    Research output: Other contributionClinical Trialpeer-review


    Peripheral arterial disease (PAD) is associated with cerebral and coronary artery disease. Symptomatic PAD affects about 5% of people over 55 years; many more have asymptomatic PAD. Early detection enables modification of arterial disease risk factors. Diagnostically, assessment of symptoms or signs can be unreliable; ankle brachial pressure index (ABPI) testing is time-consuming and few healthcare professionals are properly trained. This study assessed the diagnostic accuracy of multi-site photoplethysmography (MPPG), an alternative non-invasive test for PAD, in primary care. PAD patients identified from general practice registers were age- and sex-matched with controls. Participants were assessed using MPPG, ABPI and duplex ultrasound (DUS). Outcome measures were sensitivity and specificity of MPPG and ABPI (relative to DUS) and concordance. MPPG test results were available in 249 of 298 eligible participants from 16 practices between May 2015 and November 2016. DUS detected PAD in 101/249 (40.6%). MPPG sensitivity was 79.8% (95% confidence interval [CI] 69.9–87.6%), with specificity 71.9% (95% CI 63.7–79.2%). ABPI sensitivity was 80.2% (95% CI 70.8–87.6%), with specificity 88.6% (95% CI 82–93.5%). With comparable sensitivity to ABPI, MPPG is quick, automated and simpler to do than ABPI; it offers the potential for rapid and accessible PAD assessments in primary care.
    Original languageEnglish
    TypeISRCTN Summary of work published on device project with formal clinical trial
    Media of outputOnline ISRCTN webpage
    PublisherBMJ Publishing Group
    Publication statusPublished - 24 Oct 2022


    Dive into the research topics of 'Novel pulse device for diagnosis of peripheral arterial disease (NOTEPAD): ISRCTN13301188'. Together they form a unique fingerprint.

    Cite this